Full Text View
Tabular View
No Study Results Posted
Related Studies
Multiple Class I Peptides & Montanide ISA 51 VG w Escalating Doses of Anti-PD-1 Antibody BMS936558
This study is ongoing, but not recruiting participants.
Study NCT01176474   Information provided by H. Lee Moffitt Cancer Center and Research Institute

First Received on August 5, 2010.   Last Updated on January 2, 2013   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Melanoma (Skin)
Additional conditions recognized in this trial
Melanoma
More general conditions related to this trial
Neoplasms
Neoplasms by Histologic Type
Neoplasms, Germ Cell and Embryonal
Neoplasms, Nerve Tissue
Neuroectodermal Tumors
Neuroendocrine Tumors
Nevi and Melanomas
Interventions listed in this trial
NY-ESO-1
BMS-936558
gp100:280-288(288V)
Montanide
Additional drug interventions recognized in this trial
Antibodies
Freund's Adjuvant
Immunoglobulins
More general drug interventions related to this trial
Adjuvants, Immunologic
Immunologic Factors
Pharmacologic Actions
Physiological Effects of Drugs
Sponsors listed in this trial
H. Lee Moffitt Cancer Center and Research Institute
National Cancer Institute (NCI)
Medarex
Bristol-Myers Squibb


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services